炎症性肠病
药物输送
医学
药品
靶向给药
病理生理学
疾病
胃肠道
药理学
生物信息学
重症监护医学
纳米技术
病理
内科学
生物
材料科学
作者
Sahar Mohajeri,Saeed Moayedi,Shabnam Mohajeri,Abbas Yadegar,Ismaeil Haririan
标识
DOI:10.3389/fphar.2022.1045575
摘要
Inflammatory bowel disease (IBD) is a gastrointestinal disorder, affecting about several million people worldwide. Current treatments fail to adequately control some clinical symptoms in IBD patients, which can adversely impact the patient’s quality of life. Hence, the development of new treatments for IBD is needed. Due to their unique properties such as biocompatibility and sustained release of a drug, biomaterials-based drug delivery systems can be regarded as promising candidates for IBD treatment. It is noteworthy that considering the pathophysiological changes occurred in the gastrointestinal tract of IBD patients, especially changes in pH, surface charge, the concentration of reactive oxygen species, and the expression of some biomolecules at the inflamed colon, can help in the rational design of biomaterials-based drug delivery systems for efficient management of IBD. Here, we discuss about targeting these pathophysiological changes using biomaterials-based drug delivery systems, which can provide important clues to establish a strategic roadmap for future studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI